B7-33Tissue RepairSafety Rating 6/10
Primary research areaAnti-fibrotic therapy (heart
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose rangeResearch compound. Animal studies: 0.5 mg/kg SC daily. Human protocols not established.
AdministrationVaries
Safety6/10 · Not FDA-approved
NCAA D1Not listed
Price Comparison
Compare vendors
Overview
About B7-33
Mechanism of action
Single-chain analogue of H2 relaxin B-chain; selectively activates RXFP1 receptor; anti-fibrotic via collagen remodeling; vasodilatory; cardioprotective without uterine relaxation effects.
Safety profile
Limited human data. Vasodilation (hypotension); generally well-tolerated in animal studies. · Preclinical compound; no adverse signals in studies; anti-fibrotic potential; early stage
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops B7-33 below your target.
Related pages